FM

Frazier Management Portfolio holdings

AUM $1.12M
1-Year Est. Return 150.24%
This Quarter Est. Return
1 Year Est. Return
+150.24%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$1.99M
AUM Growth
-$1.3B
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
43
New
Increased
Reduced
Closed

Top Buys

No buys this quarter

Top Sells

1
+$175M
2
+$115M
3
+$70.4M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$60.7M
5
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$60M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRA
1
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.75M 88.13%
54,654
-1,210,207
ALNA
2
DELISTED
Allena Pharmaceuticals
ALNA
$236K 11.87%
1,019,288
-632,069
PCVX icon
3
Vaxcyte
PCVX
$5.5B
– –
-2,309,554
ACRS icon
4
Aclaris Therapeutics
ACRS
$206M
– –
-408,329
ANAB icon
5
AnaptysBio
ANAB
$969M
– –
-899,700
ARQT icon
6
Arcutis Biotherapeutics
ARQT
$2.5B
– –
-8,434,232
ARVN icon
7
Arvinas
ARVN
$699M
– –
-163,763
AUTL
8
Autolus Therapeutics
AUTL
$431M
– –
-3,746,857
AVDL
9
Avadel Pharmaceuticals
AVDL
$1.48B
– –
-951,814
BCYC
10
Bicycle Therapeutics
BCYC
$566M
– –
-555,240
COGT icon
11
Cogent Biosciences
COGT
$2.29B
– –
-1,774,891
CRNX icon
12
Crinetics Pharmaceuticals
CRNX
$3.91B
– –
-1,384,293
EPIX
13
DELISTED
ESSA Pharma
EPIX
– –
-543,470
IMVT icon
14
Immunovant
IMVT
$3.05B
– –
-585,759
IOVA icon
15
Iovance Biotherapeutics
IOVA
$789M
– –
-1,747,622
KALV icon
16
KalVista Pharmaceuticals
KALV
$561M
– –
-1,305,087
KRYS icon
17
Krystal Biotech
KRYS
$5.51B
– –
-771,250
MIRM icon
18
Mirum Pharmaceuticals
MIRM
$3.69B
– –
-3,566,912
MRUS icon
19
Merus
MRUS
$7.19B
– –
-559,179
PASG icon
20
Passage Bio
PASG
$25.7M
– –
-250,461
PHAT icon
21
Phathom Pharmaceuticals
PHAT
$919M
– –
-5,827,415
REPL icon
22
Replimune Group
REPL
$351M
– –
-650,862
RGNX icon
23
Regenxbio
RGNX
$593M
– –
-235,809
SLN
24
Silence Therapeutics
SLN
$307M
– –
-886,173
SNDX icon
25
Syndax Pharmaceuticals
SNDX
$1.23B
– –
-2,772,062
1
2